A charitable initiative backed by Edwards Lifesciences Corp. announced that it has educated, screened and/or treated more than 400,000 underserved individuals for heart valve disease since 2014.
The initiative, called Every Heartbeat Matters, is on track to meet its goal of reaching 1 million underserved people by 2020, according to a press release issued by the company.
“Millions of people around the world suffer from heart valve disease, yet unbeknown to most, the disease is highly treatable once detected,” Maurice E. Sarano, MD, professor of medicine at Mayo Medical School and director of the Valvular Heart Disease Clinic at Mayo Clinic.
The initiative supports nonprofit organizations through grants from Edwards Lifesciences Foundation and donations of Edwards valves for care of indigent individuals; more than $15 million has been invested so far, according to the release.
“Our Every Heartbeat Matters partners are bringing strategic philanthropy, passion and commitment to help vulnerable people all around the world who are affected by heart valve disease,” Michael A. Mussallem, chairman and CEO of Edwards Lifesciences and chairman of Edwards Lifesciences Foundation. “We are proud to help fuel their bold and impactful work and are on track to achieve our collective pursuit of helping one million underserved people by 2020.”
Disclosure: Mussallem is an employee of Edwards Lifesciences. Sarano reports consulting for Edwards Lifesciences and the Edwards Lifesciences Foundation.